
The study examines the impact of background beta-blocker treatment on the efficacy of sacubitril/valsartan in heart failure with reduced ejection fraction. In the PARADIGM-HF trial, sacubitril/valsartan reduced the risk of heart failure hospitalization and cardiovascular death more in patients not receiving beta-blockers. The benefits were more pronounced in this group, particularly for cardiovascular death and all-cause mortality. Sacubitril/valsartan remained effective regardless of beta-blocker use.
Like
Save
Share